Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Recent Advances in Formulating and Processing Biomaterial Inks for Vat Polymerization-Based 3D Printing

Li W., Mille LS., Robledo JA., Uribe T., Huerta V., Zhang YS.

Narrative Review, published in Adv Healthc Mater (2020) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Adv Healthc Mater (2020)
Reported sample size
—
Source database
Europe PMC
PMID
32529775
PMCID
PMC7473482
DOI
10.1002/adhm.202000156
Citations
130

Abstract (original English)

3D printing and bioprinting have become a key component in precision medicine. They have been used toward the fabrication of medical devices with patient-specific shapes, production of engineered tissues for in vivo regeneration, and preparation of in vitro tissue models used for screening therapeutics. In particular, vat polymerization-based 3D (bio)printing as a unique strategy enables more sophisticated architectures to be rapidly built. This progress report aims to emphasize the recent advances made in vat polymerization-based 3D printing and bioprinting, including new biomaterial ink formulations and novel vat polymerization system designs. While some of these approaches have not been utilized toward the combination with biomaterial inks, it is anticipated their rapid translation into biomedical applications.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansBiocompatible MaterialsInkPolymerizationBioprintingPrinting, Three-Dimensional

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.